Research article
Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis
Tina Papastavros, Lisa R. Dolovich, Anne Holbrook, Lori Whitehead and Mark Loeb
CMAJ July 23, 2002 167 (2) 131-136;
Tina Papastavros
From *the Faculty of Pharmacy, University of Toronto, Toronto, Ont.; †the Centre for Evaluation of Medicines and ‡the Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, Ont.; the Departments of §Family Medicine and ¶Medicine and the **Division of Clinical Pharmacology, McMaster University, Hamilton, Ont.
Lisa R. Dolovich
From *the Faculty of Pharmacy, University of Toronto, Toronto, Ont.; †the Centre for Evaluation of Medicines and ‡the Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, Ont.; the Departments of §Family Medicine and ¶Medicine and the **Division of Clinical Pharmacology, McMaster University, Hamilton, Ont.
Anne Holbrook
From *the Faculty of Pharmacy, University of Toronto, Toronto, Ont.; †the Centre for Evaluation of Medicines and ‡the Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, Ont.; the Departments of §Family Medicine and ¶Medicine and the **Division of Clinical Pharmacology, McMaster University, Hamilton, Ont.
Lori Whitehead
From *the Faculty of Pharmacy, University of Toronto, Toronto, Ont.; †the Centre for Evaluation of Medicines and ‡the Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, Ont.; the Departments of §Family Medicine and ¶Medicine and the **Division of Clinical Pharmacology, McMaster University, Hamilton, Ont.
Mark Loeb
From *the Faculty of Pharmacy, University of Toronto, Toronto, Ont.; †the Centre for Evaluation of Medicines and ‡the Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, Ont.; the Departments of §Family Medicine and ¶Medicine and the **Division of Clinical Pharmacology, McMaster University, Hamilton, Ont.
In this issue
Article tools
Respond to this article
Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis
Tina Papastavros, Lisa R. Dolovich, Anne Holbrook, Lori Whitehead, Mark Loeb
CMAJ Jul 2002, 167 (2) 131-136;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Current Treatment Options for Latent Tuberculosis Infection
- Treatment of latent infection with Mycobacterium tuberculosis: update 2010
- Tuberculosis contact investigation in low prevalence countries: a European consensus
- Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort
- High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis
- Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study